Literature DB >> 26298198

Reexcision for positive margins in breast cancer: A predictive score of residual disease.

Myriam Mimouni1, Fabrice Lecuru2, Roman Rouzier3, Noémie Lotersztajn4, Denis Heitz5, Julien Cohen6, Arnaud Fauconnier7, Cyrille Huchon8.   

Abstract

BACKGROUND: Guidelines recommend re-excision if resection margins are positive in lumpectomy for breast cancer. However, residual disease (RD) is not always found. The aim of our study was to develop a score to predict RD in re-excision specimens.
MATERIALS AND METHODS: We carried out a multicenter, retrospective study with two population groups. The 'modeling' group was composed of 148 patients treated in the Centre Hospitalier Poissy-St-Germain or the Georges Pompidou European Hospital and the 'validation' group was composed of 67 patients treated in Curie Institute. The score was built with a logistic regression model.
RESULTS: Factors independently associated with RD were: a cumulative length of all positive margins>5 mm, invasion by ductal carcinoma in situ only, a pathological tumor size>30 mm and a pathological tumor size<30 mm with a discrepancy of >50% between pathological and radiological tumor size. The 7-point score allowed the classification of patients into three risk groups for RD: low (16% of patients experienced RD), moderate (65%) and high (100%). The areas under the ROC curve of the score and the logistic model were 0.72(95%CI:0.68-0.75,p = 0.60). The proportion of RD in each group of the validation population (25%, 48%, and 100% in the low, moderate and high group, respectively) confirmed the accuracy of the score in an independent population.
CONCLUSIONS: This score enables the identification of patients at high risk of RD but it cannot provide guidance for the decision to undertake re-excision surgery in the low-risk group. Further studies are needed to test the score in extensive datasets and better identify low-risk patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Breast conserving therapy; Predictive score; Re-excision; Residual disease

Mesh:

Substances:

Year:  2015        PMID: 26298198     DOI: 10.1016/j.suronc.2015.08.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  5 in total

1.  Prognostic factors for residual occult disease in shave margins during partial mastectomy.

Authors:  Julie B Siegel; Rupak Mukherjee; Yeonhee Park; Abbie R Cluver; Catherine Chung; David J Cole; Mark A Lockett; Nancy Klauber-DeMore; Andrea M Abbott
Journal:  Breast Cancer Res Treat       Date:  2021-06-16       Impact factor: 4.872

2.  The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer.

Authors:  Piero Fregatti; Marco Gipponi; Giulia Atzori; Raffaele DE Rosa; Raquel Diaz; Chiara Cornacchia; Marco Sparavigna; Alessandro Garlaschi; Liliana Belgioia; Alessandra Fozza; Francesca Pitto; Luca Boni; Eva Blondeaux; Francesca Depaoli; Federica Murelli; Simonetta Franchelli; Gabriele Zoppoli; Matteo Lambertini; Daniele Friedman
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

3.  Radiological Underestimation of Tumor Size Influences the Success Rate of Re-Excision after Breast-conserving Surgery.

Authors:  Duncan Simpson; Jennifer Allan; Brendan McFall
Journal:  Eur J Breast Health       Date:  2021-10-04

4.  Handheld macroscopic Raman spectroscopy imaging instrument for machine-learning-based molecular tissue margins characterization.

Authors:  François Daoust; Tien Nguyen; Patrick Orsini; Jacques Bismuth; Marie-Maude de Denus-Baillargeon; Israel Veilleux; Alexandre Wetter; Philippe Mckoy; Isabelle Dicaire; Maroun Massabki; Kevin Petrecca; Frédéric Leblond
Journal:  J Biomed Opt       Date:  2021-02       Impact factor: 3.170

5.  Outcomes of Margin Reexcision after Oncoplastic Breast Reduction.

Authors:  Tasha A Martin; Salman Choudhry; Luther H Holton; W Charles Mylander; Lorraine Tafra; Wen Liang; Rubie Sue Jackson
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.